Correlation Between Eliem Therapeutics and Trevi Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Eliem Therapeutics and Trevi Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Eliem Therapeutics and Trevi Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Eliem Therapeutics and Trevi Therapeutics, you can compare the effects of market volatilities on Eliem Therapeutics and Trevi Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Eliem Therapeutics with a short position of Trevi Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Eliem Therapeutics and Trevi Therapeutics.

Diversification Opportunities for Eliem Therapeutics and Trevi Therapeutics

0.54
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Eliem and Trevi is 0.54. Overlapping area represents the amount of risk that can be diversified away by holding Eliem Therapeutics and Trevi Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Trevi Therapeutics and Eliem Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Eliem Therapeutics are associated (or correlated) with Trevi Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Trevi Therapeutics has no effect on the direction of Eliem Therapeutics i.e., Eliem Therapeutics and Trevi Therapeutics go up and down completely randomly.

Pair Corralation between Eliem Therapeutics and Trevi Therapeutics

Given the investment horizon of 90 days Eliem Therapeutics is expected to under-perform the Trevi Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Eliem Therapeutics is 3.21 times less risky than Trevi Therapeutics. The stock trades about -0.05 of its potential returns per unit of risk. The Trevi Therapeutics is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  286.00  in Trevi Therapeutics on September 15, 2024 and sell it today you would earn a total of  131.00  from holding Trevi Therapeutics or generate 45.8% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy71.43%
ValuesDaily Returns

Eliem Therapeutics  vs.  Trevi Therapeutics

 Performance 
       Timeline  
Eliem Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
Trevi Therapeutics 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Trevi Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady basic indicators, Trevi Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Eliem Therapeutics and Trevi Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Eliem Therapeutics and Trevi Therapeutics

The main advantage of trading using opposite Eliem Therapeutics and Trevi Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Eliem Therapeutics position performs unexpectedly, Trevi Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Trevi Therapeutics will offset losses from the drop in Trevi Therapeutics' long position.
The idea behind Eliem Therapeutics and Trevi Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments